Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab versus pemetrexed plus platinum as first-line therapy for unresectable pleural mesothelioma
2016-001859-43Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pleural mesothelioma comparing Nivolumab + ipilimumab with Pemetrexed + cisplatin or carboplatin (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Oct 2016; status: completed.
02
Drugs
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2016-001859-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001859-43.